InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

Current share price for ATX : $0.140 0.01 (6.67%)+

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$72 Results of Annual General Meeting 18 Sep 2020 11:11AM $0.150 $0.140 fallen by 6.67%
$72 CEO Presentation to AGM 18 Sep 2020 9:34AM $0.150 $0.140 fallen by 6.67%
$72 Amplia Receives Ethics Clearance fo Conduct Phase 1 Trial 8 Sep 2020 8:24AM $0.130 $0.140 risen by 7.69%
$72 Appendix 3G - Notification of Issue of Securities - Options 2 Sep 2020 6:00PM $0.130 $0.140 risen by 7.69%
$72 Amplia Appoints Dr Mark Devlin as Chief Scientific Officer 31 Aug 2020 9:22AM $0.135 $0.140 risen by 3.70%
$72 Notice of Annual General Meeting & Proxy - YE 31 March 2020 17 Aug 2020 10:03AM $0.150 $0.140 fallen by 6.67%
$72 Change in substantial holding 6 Aug 2020 1:14PM $0.135 $0.140 risen by 3.70%
$72 Change in substantial holding 6 Aug 2020 8:47AM $0.130 $0.140 risen by 7.69%
$72 Change of Director Interest - Dr Lambert - Entitlement Offer 5 Aug 2020 6:19PM $0.130 $0.140 risen by 7.69%
$72 Change of Directors Interest - Dr W Tong - Entitlement Offer 5 Aug 2020 5:01PM $0.130 $0.140 risen by 7.69%
$72 Appendix 2A - Retail Entitlement Offer 4 Aug 2020 8:18AM $0.150 $0.140 fallen by 6.67%
$72 Appendix 4G - Key to Corporate Governance Disclosures 31 Jul 2020 11:30AM $0.160 $0.140 fallen by 12.50%
$72 2020 Corporate Governance Statement 31 Jul 2020 11:30AM $0.160 $0.140 fallen by 12.50%
$72 Annual Report to Shareholders - YE 31 March 2020 31 Jul 2020 11:30AM $0.160 $0.140 fallen by 12.50%
$72 Entitlement Offer Completed 30 Jul 2020 9:53AM $0.165 $0.140 fallen by 15.15%
$72 Quarterly Activities and Cashflow Reports - June 2020 27 Jul 2020 8:22AM $0.155 $0.140 fallen by 9.68%
$72 Nucleus Network Appointed to Conduct Phase 1 Clinical Trial 23 Jul 2020 8:36AM $0.165 $0.140 fallen by 15.15%
$72 AGM to be held Friday 18 September 2020 20 Jul 2020 4:01PM $0.165 $0.140 fallen by 15.15%
$72 Change of Director's Interest Notice - Dr. Warwick Tong 14 Jul 2020 5:05PM $0.135 $0.140 risen by 3.70%
$72 Becoming a substantial holder 14 Jul 2020 12:12PM $0.145 $0.140 fallen by 3.45%
$72 Becoming a substantial holder 14 Jul 2020 11:11AM $0.115 $0.140 risen by 21.74%
$72 Change in substantial holding 14 Jul 2020 10:40AM $0.115 $0.140 risen by 21.74%
$72 Appendix 2A - Institutional Entitlement Offer 10 Jul 2020 4:27PM $0.105 $0.140 risen by 33.33%
$72 Entitlement Offer - Despatch of Retail Offer Booklet 8 Jul 2020 6:03PM $0.115 $0.140 risen by 21.74%
$72 Institutional Entitlement Offer Completed 3 Jul 2020 9:25AM $0.125 $0.140 risen by 12%

401 - 425 of 530 results

Page 17 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.